EMBO JOURNAL-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-10-19 PILIXIA 来自上海

请问一审周期是多久呢

22 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-11-25 ms2000000406721606

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：细胞生物学
经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开

24 0

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-10-22 slientwo

偏重的研究方向：分子生物学;细胞生物学
经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。

65 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-05-25 148a4d45m01暂无昵称来自上海

编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~

41 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2018-07-20 毛大丁

已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？

442 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-04-20 tomsyu

这个杂志送审后会是什么状态？会有出现review zip吗

79 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-03-14 ms4000000641054978

这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？

76 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2018-08-23 liuzx4360

under editorial consideration 多久送审？发表过的前辈请明示。

401 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2017-09-22 iseeyou1210

我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.

571 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560340, encodeId=ae5a56034009, content=under editorial consideration 多久送审？发表过的前辈请明示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BBD2F79E093356C927955564EDF09FB3/100, createdBy=cd792425993, createdName=liuzx4360, createdTime=Thu Aug 23 02:07:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547504, encodeId=d34b54e50470, content=我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=571, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Fri Sep 22 11:45:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089978, encodeId=d32510899e852, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 小动量

每个期刊梯度一般情况下选择几个备选期刊合适？

79 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务